Two monoclonal antibodies, E3cD8 and E3cA10, were generated to the EBNA 3c nuclear protein from the B95.8 isolate of Epstein-Barr virus (EBV). Both antibodies efficiently precipitate EBNA 3c from B95.8transformed lymphoblastoid cell lines, and E3cA10 also detects EBNA 3c on Western blots. Whereas E3cD8 reacts with all 11 Typed isolates of EBV tested, and E3cA10 reacts with 14 of 17 Type-1 isolates, neither antibody detects the EBNA 3c protein encoded by Type-2 isolates. E3cD8 recognizes a peptide sequence (PA/rPQAPYQGY) in a repeat region of the B95.8 EBNA 3c coding sequence which is not present in the prototype Type-2 AG876 sequence. The E3cAI0 antibody epitope has been mapped to the minimal five amino acid B95.8 peptide, WAPSV, which has an alanine to valine substitution in the AG876 virus isolate.
Introduction
Epstein-Barr virus (EBV) is carried as a persistent and largely asymptomatic infection in more than 90 % of the adult population worldwide and is also strongly implicated in certain lymphoproliferative and malignant diseases. Experimental infection of resting B lymphocytes with EBV results in the establishment of lymphoblastoid cell lines (LCLs) expressing a limited number of'latent' viral gene products, including: six nuclear proteins (EBNA 1, 2, 3a, 3b, 3c and LP), three membrane proteins (LMP 1, 2A and 2B) and two non-polyadenylated small RNAs (EBERs) (Kieff & Leibowitz, 1990) . Natural isolates of EBV may be classified into one of two groups (Type-1 or Type-2) distinguishable by sequence polymorphisms amongst the latent viral genes (Dambaugh et al., 1984; Adldinger et al., I985; Rowe et al., 1985) . The two prototype virus isolates, t Present address: Department of Genetics, Yale University School of Medicine, New Haven, Connecticut 06510, U.S.A.
:~Present address: Department of Biochemistry, University of Leicester. Leicester LE1 7RH, U.K. and AG876 (Type-2), show only approximately 50 % amino acid sequence identity in their EBNA 2 proteins (Dambaugh et al., 1984) ; lesser but significant polymorphisms are also observed in the EBNA 3a, 3b, 3c (Sample et al., 1990) and LP proteins (Bodescot et al., 1984; Dambaugh et al., 1984) . Type-2 viruses are less efficient at transforming B lymphocytes than are Type-1 viruses .
Studies using recombinant EBVs deleted for specific genes or carrying stop codon mutations in open reading frames suggest that EBNA 2, 3a and 3c are essential for the growth transformation of B lymphocytes Hammerschmidt & Sugden, 1989; Tomkinson et al., 1993) , whereas complementation studies show that EBNA LP is not essential but greatly enhances transforming efficiency (Hammerschmidt & Sugden, 1989; Mannick et aL, 1991) . LMP 1 has not yet been formally shown to be essential for B cell transformation, but its oncogenic effects in rodent fibroblasts suggest it is likely to be playing an important role (Wang et al., 1985; Baichwal & Sugden, 1988) . In human B lymphocytes this protein alone can induce many of the phenotypic changes observed when resting B cells are transformed with infectious EBV. Thus, LMP 1 can induce expression of 0001-2140 © 1994 SGM the cell surface markers CD21, CD23, CD39, CD40, CD44, ICAM1 (CD54), LFA1 (CDlla/18) and LFA3 (CD58) (Wang et al., , 1990a , and it also enhances cell survival under adverse culture conditions through upregulation of the bcl-2 oncogene (Henderson et al., 1991) . EBNA 2 can induce expression of CD21 and CD23 in B lymphocytes (Wang et al., 1987; Aman et al., 1990) , whereas EBNA 3c can induce expression of CD21 but not CD23 (Wang et al., 1990a) . No changes in cell surface phenotype have been observed in B lymphocytes transfected with EBNA LP, 3a or 3b.
Of the nuclear proteins, EBNA 1 has probably been most extensively characterized. This nuclear antigen is a site-specific DNA-binding protein that binds to two sites in the EBV origin of replication (oriP) and is required for replication and maintenance of the viral episome (Yates et al., 1984 (Yates et al., , 1985 . EBNA 2, in addition to inducing expression of the cellular genes CD21 and CD23~ has been shown to trans-activate expression of the other latent genes (Abbot et al., 1990; Wang et al., 1990b; Woisetschlaeger et al., 1991) . Although EBNA 2responsive elements have been defined in both cellular and viral promoter regions (Sung et al., 1991; Wang et al., 1991 ; Woisetschlaeger et al., 1991 ; Zimber-Strobl et at., 1993) , no specific nucleotide binding properties have been described for EBNA 2. However, interactions with cellular proteins and an associated ATPase activity have been reported (Randahl et al., 
1992; Gr/isser et al., 1993). Comparatively little is known about the biochemical properties and functions of the remaining EBNAs.
It was recently reported that EBNA 3c can induce expression of LMP 1 when transfected into the Burkitt's lymphoma (BL) cell line Raji which carries an isolate of EBV with a deleted EBNA 3c gene (Allday et al., 1993) . This observation, taken together with the effect of EBNA 3c on the expression of the B cell activation antigen CD21 (Wang et at., 1990a), suggests that EBNA 3c acts as a trans-activator of gene expression. The EBNA 3c protein sequence has features in common with the bZIP family of transcription factors which includes fos and jun. It contains a basic region and a domain with homology to the leucine zipper motif found in these sequence-specific DNA-binding proteins (Allday et al., 1993) . Detailed investigations into the functions and properties of EBNA 3c have been hindered by the lack of monoclonal antibody (MAb) reagents to this protein. In the present study we generated two MAbs to EBNA 3c, designated E3cA10 and E3cD8. In the course of characterizing these antibodies we observed that E3cA 10, but not E3cD8, unexpectedly coprecipitated EBNA 2 from lysates of EBV-transformed LCLs, The possibility of a direct interaction between these two latent proteins was investigated.
Methods
Cell lines'. Several LCLs, each transformed with a different strain of EBV, were used in this study. Most of these LCLs were established by refection of adult seronegative blood samples (CD, CR, PR, JTo RE or NAD) or of umbilical cord blood samples (C1 and C2) with Type-1 or Type-2 viruses from BL cells Rowe et al., 1989) or from a nasopharyngeal carcinoma biopsy (Hitt et al., 1989) . The Zost-1 LCL is an EBV-transformed line established by spontaneous outgrowth from the blood of a patient receiving acyclovir treatment (Rowe etal., 1989) . The Raji line (Pulvertaft, 1965 ) is a BL-derived tumour cell line carrying a Type-1 strain of EBV in which the EBNA 3c gene is deleted (Polack et al., 1984) . LCLs and BL lines were maintained in suspension culture at 37 °C in RPMI 1640 medium supplemented with 10 % fetal calf serum and antibiotics, and were passaged twice-weekly by splitting 1 : 5 in fresh medium. The human osteosarcoma cell line, TK-143, was maintained as adherent cell cultures in Dulbecco's MEM supplemented with 10 % fetal calf serum and antibiotics, and was passaged by trypslnization and splitting l : 10 m fresh medium.
Generation of MAbs.
A bacterial fl-galactosidase fusion protein, pTLE4, containing residues 439 to 781 from the B95.8 EBNA 3c coding sequence was constructed and purified as described (Petti et al., 1988) . BALB/c mice were primed intraperitoneally with 50 ~tg of fusion protein antigen in complete Freund's adjuvant, boosted intraperitoneally at 3 weeks with a further 50 gg of antigen in alum adjuvant and at 6 weeks with 50 ~g of antigen without adjuvant. Three days after the final boost the spleen cells were collected and fused with the mouse myeloma line X63-Ag. 653, and hybridomas were selected as described previously . The pTLE4 fusion protein and figalactosldase protein were used as target proteins in ELISAs performed as preliminary screens for antibody-secreting hybridomas of interest. Hybridomas secreting antibodies specific for EBNA 3c were further characterized by immunoprecipitation and immunoblottmg. In this manner two hybridomas, E3cA10 and E3cD8, were generated and used in the present study. Production of the PE2 hybridoma, producing antibodies to EBNA 2, has been described previously .
Recombinant vacc#tia viruses. EBV recombinant vaccinia viruses
were provided by Dr M. G. Kurilla (Harvard Medical School, Boston, Mass., U.S.A.) and Dr M. Macken (Paterson Institute for Cancer Research, Manchester, U.K.), and have been described elsewhere (Murray et al., 1990) . All coding sequences were derived from the B95.8 Type-1 EBV sequence, with the exception of the Type-2 EBNA 2 seque~ace which was derived from the AG876 strain of EBV. Infection of TK-143 cells with recombinant vaccinia viruses was performed by exposing confluent 9 cm dishes of TK-143 cells to 1.5 ml of virus (giving an m.o.i, of 5) for 2 h at 37 °C. Following the addition of fresh growth medium, the infected cells were incubated for a further 14 h before harvesting.
hnmunoprectpitation. Suspension cell cultures were harvested and washed twice in PBS pH 7.2, then lysed on ice with RIPA buffer (20 mM-Tris-HC1 pH 7"5, 150 mM-NaC1, 0.5% Triton X-100, 0.5% sodmm deoxycholate, 0-1% SDS and 5 mM-EDTA) at a concentration of 40 x 10 n cells/ml. For the adherent TK 143 cells infected with vaccinia virus, cells from two confluent 9 cm dishes were recovered by trypsinization, washed twice m PBS, and lysed with 1 ml RIPA buffer. In both cases, RIPA lysates were sonicated for 40 s on ice and then clarified by centrifngation at 13000g for 15min at 4 °C. For each immunoprecipitation, 0.5 ml clarified lysate was added to 80 gl of a 1 : 1 slurry of MAb-coated beads prepared by preincubating Sepharose-Protein A beads first with 8 gl polyclonal rabbit anti-mouse IgG antibodies (Dakopatts; Z259) and then with 500 lal of MAb-containing culture supernatant. Immunoprecipitation of cell lysates with the IP: 54.70.40.11
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MAb-coated beads was carried out overnight at 4 °C with mixing. The beads were then washed three times in cold RIPA buffer, once in cold PBS, and finally were boiled in 100 gl of electrophoresis buffer for 2 rain to elute the immunoprecipitates for analysis by SDS-PAGE.
Detection of proteins by Western blotting. Cell extracts and
immunoprecipitates were separated by discontinuous SDS-PAGE as described previously (Rowe et al., 1989) . Briefly, immunoprecipitates or extracts from 10 ~ cells solubilized in electrophoresis buffer were separated on 7.5 or 10% gels and, after protein transfer by electroblotting, the nitrocellulose filters were probed either with murine MAbs followed by rabbit anti-mouse IgG polyclonal antibodies, or with human antibodies. In both cases specifically bound antibodies were detected by 12~I-Protein A and autoradiography. For analysis of lmmunoprecipitates by Western blotting, a human synovial fluid from a rheumatoid arthritis patient, RS22, was used either alone or pooled with two other human sera (pool PB/AM/RS22): these polyspecific reagents reacted with all six EBNAs encoded by Type-1 strains of EBV and also showed cross-reactivity with the EBNAs 1, 2, 3a and LP encoded by Type-2 strains of EBV, ELISAs. Flexible polyvinyl ELISA plates (Falcon) were coated with the pTLE4 EBNA 3c fusion protein (Petti et al., 1988) at 5 ~tg/ml in 0"1 M-bicarbonate buffer pH 9.5 at 4 °C overnight. The plates were washed three times in PBS containing 0.1% Tween and were blocked at 37 °C for 1 h with 1% BSA in PBS-Tween. Plates were then given a further three washes in PBS-Tween. MAb supernatants (diluted 1/20 or 1/100 in PBS) were pre-incubated with or without competing peptide (50 gM) overnight at 4 °C and then transferred to the fusion protein-coated plates for 1.5 h at room temperature. After washing, the plates were incubated at room temperature for 1 to 2 h with peroxidaseconjugated goat anti-mouse IgG (Sigma) diluted 1 : 1000 in PBS-Tween. Following five washes with PBS-Tween, the plates were developed with 1,2-phenylenediamine (OPD) (Dako S 2000) in 0.1 M-citric acidphosphate buffer for 1 to 8 rain before termination of the reaction with H2SO 4 and measurement of A49 o.
Preparation of DNA Jor sequencing. Approximately 107 to 2 × 107 cells were washed in PBS and lysed at 50 °C for 1 to 2 h in 500 gl lysis solution containing 0.5 % Tween and 1 mg/ml Proteinase K in Taq incubation buffer (Boehringer). The Proteinase K was then inactivated at 100 °C for 10 mm. DNA was amplified across the 13 amino acid triple repeat region of the EBNA 3c open reading frame using primers KF60 (EBV coordinates 100395 to 100415) and KF63 (EBV coordinates 101099 to 101119) in 100 ~1 reaction mixtures containing 10 gl of cell lysate, 10 gl of dNTP mix (2 mM of each of dATP, dCTP and dTTP, 0-5 mM-dGTP and 1.5 mM-7-deaza-dGTP), 10 gl of each primer at 10 gM, and 1% DMSO in Taq incubation buffer. Samples were overlaid with mineral oil and preheated to 94 °C for 5 min before the addition of 0.5 gl (2.5 units) of Taq polymerase (Boehringer). PCR was performed at 94 °C for 60 s, 50 °C for 60 s, 72 °C for 120 s for 35 cycles in a Perkin-Elmer Cetus DNA thermal cycler. A 50 gl aliquot of the amplified reaction was electrophoresed through a 1% low melting point agarose gel and the predominant band was excised and purified using the Magic PCR preps DNA purification system (Promega) to give a final sample volume of 50 gl.
Cycle sequencing of amplified products. Sequencing of the amplified product was carried out in the 5' to 3' direction using the KF60 primer and the Perkln-Elmer Cetus Amplitaq cycle sequencing kit. One gl of a 10 p.M primer solution was 5' end-labelled with 50 gCi of [?,-32P]ATP using 10 units of T4 polynucleotide kinase (Boehringer) in a final volume of 20 gl. The kinase was inactivated by heating to 94 °C before use. For each DNA sample to be sequenced, a master mix containing 15 pl of DNA, 4 gl of 10 x cycling mix and 1 tal of labelled primer was prepared, and 4 Ixl aliquots were added to each of four PCR tubes containing 4 gl of the dideoxynucleotides A, C, G or T. The sequencing PCR was performed at 94 °C for 30 s, 50 °C for 30 s, 72 °C for 60 s for 30 cycles, and terminated by addition of 3 gl stop solution. Samples were heated to 70 °C for 2 rain and 3 gl portions were separated on a 6 % sequencing gel which was then fixed, dried and autoradiographed.
Results

Generation of two MAbs to EBNA 3c
A fl-galactosidase fusion protein, pTLE4, containing residues 439 to 781 of the EBNA 3c protein from the B95.8 isolate of EBV was used to immunize a BALB/c mouse which provided the spleen cells for fusion with the myeloma line X63-Ag. 653. Antibody-producing hybridoma colonies were identified by screening culture supernatants for reactivity with the pTLE4 fusion protein in ELISA. Clones reactive with pTLE4 but not with/5galactosidase in this preliminary screen were subsequently characterized for reactivity with EBNA 3c expressed in LCLs transformed with the B95.8 isolate (Type-l) of EBV. None of the hybridomas produced antibodies reactive with LCLs in immunofluorescence tests on fixed cells. However, one MAb (E3cA10) reacted with EBNA 3c both in immunoprecipitation and in Western blotting tests, and a second MAb (E3cD8) reacted with EBNA 3c in immunoprecipitation experiments only.
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Reactivity of the E3cAIO antibody to EBNA 3c is Type-1 specific
The specificity of the E3cA10 M A b is illustrated by the Western blot experiment in Fig. 1 The three Type-1 EBV isolates with which no E3cA10 reactivity was observed (BL37, Zost-1 and C15) do in fact encode E B N A 3c proteins since they can be immunoprecipitated by the E3cD8 MAb, which reacted with the E B N A 3c proteins in all (11/l 1) Type-1 isolates tested ( Fig. 2 a and 3 a, and data not shown). Because metabolic radiolabelling of E B N A 3c in LCLs is very inefficient (data not shown), these immunoprecipitation studies were performed on non-radioactive cell lysates and the products were subsequently analysed by Western blotting with E B N A 3c-reactive h u m a n sera. The disadvantages o f this approach is that the h u m a n sera used to detect immunoprecipitated E B N A 3c are typespecific, and that although high-titre antisera to Type-1 E B N A 3c are comparatively easy to identify, reagents recognizing Type-2 EBNA 3c are rare and poorly characterized. Using this technique, therefore, it was not possible to determine with certainty whether or not the E3cD8 MAb reacted with Type-2 EBNA 3c. However, subsequent experiments in which the peptide epitope specificity was mapped (see later, Fig. 6 ) showed that the E3cD8 MAb is specific for Type-1 EBNA 3c.
Immunoprecipitation of EBNA 2 by E3cAIO
Immunoprecipitation studies using E3cA 10 unexpectedly revealed that in addition to EBNA 3c this antibody could also precipitate EBNA 2 (Fig. 2 a) although no reactivity to EBNA 2 was seen on Western blots probed with E3cA10 (Fig. 1) . As a precaution, the original E3cA10 hybridoma was recloned, and all subclones demonstrated the same ability to coprecipitate EBNA 2. It should be noted in Fig. 2 that the E3cD8 MAb did not coprecipitate EBNA 2. Furthermore, several other control MAbs with irrelevant specificities did not coprecipitate EBNA 2 under these conditions. Such antibodies included OTIX-1 specific for EBNA 1, JF186 specific for EBNA-LP, T2.78 specific for EBNA 3a and CS. 1 4 specific for LMP 1 (data not shown).
To test the possibility that this phenomenon was the result of a physical association between the two nuclear proteins, a series of immunoprecipitation experiments was carried out with cell lines in which E3cA10 does not react with EBNA 3c. It was reasoned that if EBNA 2 is precipitated as a result of a physical interaction between EBNA 2 and EBNA 3c, then coprecipitation of EBNA 2 would be observed in only those lines where EBNA 3c was recognized by the antibody. Immunoprecipitations were therefore carried out with lysates of a representative Type-2 LCL, C D + W a n , in which E3cA10 does not react with EBNA 3c; in these circumstances no precipitation of EBNA 2 by E3cA10 was observed (Fig. 2b) . This result is compatible with the view that the two nuclear proteins are interacting. However, further immunoprecipitations with the Type-1 cell line C R + BL37, which expresses an EBNA 3c protein not recognized by E3cA10 (see Fig. 1 ), demonstrated that EBNA 2 could still be precipitated by this antibody, albeit less effÉciently than in other Type-1 cell lines (Fig.  3a ). This result was also observed with the other two Type-1 LCLs, Zost-1 and NAD-C15, found to express EBNA 3c proteins not recognized by E3cA10 (data not shown) and with the Type-1 cell line Raji which carries a virus with a deleted EBNA 3c gene but which expresses normal levels of EBNA 2 (see Fig. 3 b) . These data show that the E3cAI0 MAb can precipitate EBNA 2 even in the absence of EBNA 3c, suggesting that the phenomenon is a result of cross-reactivity of the antibody with EBNA 2.
Type-1
Type-2 EBNA 2 EBNA 2 4 . Analysis of immunoprecipltates demonstrating the Type-1 EBNA 2 specificity of E3cA10. TK-143 cells were infected with recombinant vaccinia viruses expressing Type-1 (B95.8) and Type-2 (AG876) EBNA 2 proteins and immunoprecipitations were performed with PE2 and E3cA10. Blots were probed with antibodies from a rheumatoid arthritis patient, RS22, which react with Type-1 and Type-2 EBNA 2. Lanes 1 and 3 show PE2 precipitations and lanes 2 and 4 show E3cA10 precipitations.
Reactivity of E3cAlO to EBNA 2 is EBV type-speeific
Since the immunoprecipitation of EBNA 2 was shown to be independent of the immunoprecipitation of EBNA 3c, and a direct interaction between these two proteins was therefore ruled out, the original observation with the Type-2 cell line ( Fig. 2b) suggests that the reactivity of E3cA10 to EBNA 2 is also Type-1 specific. To confirm the Type-1 specificity of the E3cA10 reactivity to EBNA 2, TK-143 osteosarcoma cells were infected with recombinant vaccinia viruses expressing the Type-1 and Type-2 EBNA 2 proteins derived from the prototype B95.8 and AG876 sequences respectively. Fig. 4 shows the results of immunoprecipitations from these infected cells. Efficient precipitation of both types of EBNA 2 was 3, 5, 7, 9, 11 and 13 show PE2 precipitations, and lanes 2, 4, 6, 8, 10, 12 1 and 3) , whereas E3cA10 precipitated only Type-1 (lane 2), and not Type-2 E B N A 2 (lane 4) . The ability o f E3cA10 to recognize E B N A 2 was therefore Type-l-specific.
D o m a i n s o f E B N A 2 required f o r recognition by E 3 c A I O
Further experiments using a series of recombinant vaccinia viruses expressing mutant E B N A 2 proteins (Type-l) were set up to define the region of E B N A 2 recognized by E3cA10. TK-143 cells were infected with each of the mutants, and replicate immunoprecipitations were performed using PE2 and E3cA10. Fig. 5 (a) shows pairs o f immunoprecipitations for each E B N A 2 mutant. As summarized in Fig. 5 (b) , all mutant E B N A 2 proteins were precipitated efficiently by the E B N A 2 M A b PE2 (lanes 1, 3, 5, 7, 9 and 11 6) . Comparison o f the regions deleted in these mutants (Fig. 5b) suggests that the N-terminal 19 amino acids m a y be required for recognition. The E B N A 2-BB and -Sp mutants are clearly not recognized by E3cA10 (lanes 8 and 12) although the recognition of the remaining two mutants E B N A 2-St and -PP is very strong, suggesting that the region ranging from amino acids 251 to 327 is also necessary for the recognition of E B N A 2 by E3cA10.
M a p p i n g the E 3 c D 8 and E 3 r A I O epitopes
To identify the E3cD8 and E3cA10 epitopes on E B N A 3c, 15-or 16-mer peptides overlapping by five amino acids along the entire B95.8 E B N A 3c coding sequence were screened for reactivity with the MAbs. F o u r peptides from one o f the repeat regions of E B N A 3c (residues 736 to 750, 741 to 755, 751 to 765 and 766 to 781) inhibited the E3cD8 M A b binding to an E B N A 3c fusion protein in competition ELISAs (Fig. 6 ; peptides 1, 2, 3 and 5), and sequence alignment o f these peptides identified a c o m m o n consensus of P A / p Q A P Y Q G Y . Peptides 2 and 5 gave the greatest inhibition, 86 and 81% respectively, whereas peptide 4, which does not contain the entire consensus sequence, gave only 20 % inhibition. However, when shorter peptides overlapping and including the consensus sequence were tested, none showed any antibody reactivity (data not shown). It is therefore possible that the longer peptides adopt a c o m m o n conformation and that it is this conformation which is recognized by E3cD8. It was noted that the AG876 Type-2 E B N A 3c sequence shows very poor h o m o l o g y across the repeat region and does not contain the 10-mer epitope sequence, thus precluding recognition of Type-2 isolates by E3cD8. Fig. 6 . Competition ELISA mapping of the E3cD8 and E3cA10 epitopes on EBNA 3c. MAbs E3cA10 and E3cD8 were preincubated with peptide (50 gM) before addition to ELISA plates coated with an EBNA 3c fusion protein, and the ability of each peptide to compete with binding of the MAb to the fusion protein was determined. Results are expressed as percentage inhibition relative to binding in the absence of peptide, i.e. 100 % inhibition corresponds to strong recognition of the peptide by the MAb. Peptide sequences correspond to the B95.8 published sequence. The left-hand histogram shows inhibition of binding of the E3cD8 MAb (1/20) to the fusion protein, and the right-hand histogram shows the corresponding inhibition of the E3cA10 MAb (1/100).
Two 15-mers (residues 676 to 690 and 681 to 695) inhibited E3cA10 binding to the fusion protein in competition ELISAs (Fig. 6; peptides 6 and 7) . Analysis of shorter overlapping peptides spanning these 15-mer peptide sequences (peptides 8 to 19) identified the minimal epitope as the five amino acid sequence WAPSV (peptide 18). This 5-mer alone was capable of inhibiting reactivity to the fusion protein by 96 %. Peptide 8, which does not contain the valine residue at position 5 in the epitope, showed only 39 % inhibition and peptide 19, which has no tryptophan at position 1, gave only 7 % inhibition (Fig. 6) .
A search of the EBNA 2 sequence for the WAPSV epitope failed to identify a homologous peptide sequence. Furthermore, ELISA of peptides spanning the regions of EBNA 2 required for E3cA10 recognition (1 to 19 and 251 to 327; see Fig. 5b ) failed to identify any peptides which could compete for E3cA10 reactivity (data not shown). It is therefore likely that E3cA10 reacts with a conformational epitope on EBNA 2. This explanation would be consistent with the observed lack of reactivity to EBNA 2 on Western blots probed with E3cA10.
Sequencing the E3cAIO epitope region in BL37, Zost-1 and C15
In Western blot analysis and immunoprecipitation experiments, three Type-1 virus isolates (C 15, Zost-1 and BL37) were identified which expressed EBNA 3c proteins not recognized by E3cA10 ( Fig. 1 and 3a, and - shown). DNA sequencing on these isolates identified a base substitution which leads to the same Ala--* Val substitution found in the AG876 Type-2 isolate at position 2 in the epitope (Fig. 7) . Fig. 7 also shows additional amino acid changes, flanking the epitope, found in the Type-2 isolate AG876. The Type-1 variant isolates are however indistinguishable from the B95.8 amino acid sequence except for the single amino acid change in the E3cA10 epitope.
To assess the degree to which the Ala---,Val substitution affects antibody reactivity, the 5-mer peptide WVPSV, corresponding to the sequence found in Type-2 isolates and in the variant Type-1 isolates, was compared with the WAPSV minimal peptide epitope in competition ELISAs over a range of concentrations ( Fig.  8a) . At the standard concentration of 25 gM used in competition ELISAs the WVPSV peptide gave 66% inhibition compared with the 96 % inhibition observed with the WAPSV peptide (Fig. 8b) . However, when a longer peptide from the Type-2 AG876 sequence was compared to the corresponding Type-1 peptide in competition ELISAs, the Type-2 peptide showed an inhibition of only 18 % compared to the 86 % inhibition shown by the corresponding Type-1 peptide (Fig. 8 b) .
Discussion
This study was prompted by the lack of available monospecific reagents to EBNA 3c, and we now report the generation of two MAbs to this viral protein. Both antibodies efficiently precipitate EBNA 3c from lysates of B95.8 EBV-transformed LCLs and one, E3cA10, also detects the protein in Western blots. The antibodies demonstrate EBV strain specificity. Whereas the E3cD8 MAb reacted with the EBNA 3c protein of all Type-1 isolates studied and the E3cA10 MAb reacted with the protein encoded by 14 of 17 Type-1 isolates, neither antibody demonstrated reactivity with the EBNA 3c protein encoded by Type-2 EBV isolates. This strain specificity was not unexpected since the two prototype EBV isolates, B95.8 (Type-l) and AG876 (Type-2) show only 72 % amino acid identity in their EBNA 3c proteins (Sample et al., 1990) .
The fine specificity of these MAbs was investigated by a competition ELISA using a series of overlapping peptides spanning the region of the EBNA 3c sequence present in the fl-galactosidase fusion protein that was used for immunization. Reactivity with E3cD8 was confined to four 15-and 16-mer peptides that spanned the 13 amino acid triple repeat region of the B95.8 EBNA 3c sequence (Fig. 6 ). Sequence alignment of these peptides identified a common consensus sequence of 10 amino acids, PA/pPQAPYQGY, which probably contains the epitope recognized by E3cD8. However, attempts to narrow down the epitope using shorter 8-mer peptides were unsuccessful. This result, taken together with the fact that E3cD8 does not recognize EBNA 3c in Western blots, suggests that the antibody recognizes a conformational epitope that is reproduced in the larger synthetic peptides but not in the shorter peptides. E3cD8 reactivity is Type-1-restricted since the AG876 EBNA 3c open reading frame does not contain the repeat region that contains the antibody epitope (Sample et al., 1990) .
The E3cA10 epitope was identified as a 5-met peptide sequence, WAPSV, corresponding to residues 682 to 686 of the B95.8 EBV EBNA 3c protein (Fig. 6 ). In the AG876 Type-2 EBNA 3c protein this epitope has a valine in place of the alanine in position 2. Interestingly, sequence analysis of this epitope demonstrated that all three Type-1 virus isolates in which the EBNA 3c protein was not recognized by E3cA 10 also showed the alanine valine substitution; outside this epitope these variant Type-1 isolates were identical to B95.8 and two other Type-1 isolates sequenced (Fig. 7) . A comparison of the two 5-mer peptides in competition ELISA confirmed that the alanine ~ valine substitution did affect the recognition by E3cA10 (Fig. 8 ). However, reactivity was only partially reduced by the alanine ~valine substitution in the 5-mer peptide; in contrast, reactivity of E3cA10 with longer peptides containing the variant sequence was almost completely abolished. This suggests that although the minimal epitope was confined to the WAPSV sequence, residues outside this region may influence binding of the antibody.
The predicted presence of a basic leucine zipper motif in the EBNA 3c amino acid sequence (Allday et al., 1993) is consistent with the putative function of EBNA 3c as a transcriptional activator. EBNA 3c has been shown to upregulate levels of the cellular CD21 protein on expression in EBV-negative BJAB cells (Wang et al., 1990a) , and most recently to upregulate LMP 1 when expressed in Raji cells (Allday et al., 1993) which carry an EBV genome with a deleted EBNA 3c gene. It has been suggested that the upregulation of LMP 1 by EBNA 3c of strain Raji may be a result of a direct cooperation with EBNA 2 (Allday et al., 1993) . EBNA 2 is known to act upon a response element upstream of the LMP 1 promoter and has been shown to upregulate LMP 1 in P3HR1 cells (Abbot et al., 1990; Wang et al., 1990b; Tsang et al., 1991) . No direct binding of EBNA 2 to DNA has been demonstrated and it has been postulated that EBNA 2 exerts its effect by modulating the activity of a repressor protein (Ffihraeus et al., 1990) , although recent reports have shown binding of EBNA 2 to the LMP 2 promoter via complexes with other proteins (Zimber-Strobl et al., 1993) . Subsequent biochemical studies have demonstrated that EBNA 2 complexes with a number of cellular proteins, including histone H1 and a 130K cellular protein present in a number of different cell types (GrSsser et al., 1993) .
Against this background, the observation (Fig. 2) that EBNA 2 was coprecipitated by the anti-EBNA 3c MAb, E3cA10, was of potential biological significance. However, E3cA10 was shown to coprecipitate the EBNA 2 protein expressed in three variant Type-1 EBV isolates in which the MAb does not react with EBNA 3c, as well as in the Raji cell line which expresses EBNA 2 but not EBNA 3c (Fig. 3) . These results ruled out the possibility that coprecipitation in these circumstances was due to a direct interaction between EBNA 3c and EBNA 2.
The most obvious explanation of these results is that the E3cA10 MAb cross-reacts with EBNA 2. However, the WAPSV epitope is not present in the EBNA 2 sequence. Furthermore, mapping of the EBNA 2 reactivity using mutant EBNA 2 proteins expressed by recombinant vaccinia viruses identified regions of the EBNA 2 protein required for recognition, but analysis of synthetic peptides spanning these regions could not identify a MAb-binding epitope. An alternative interpretation is that E3cA10 precipitates EBNA 2 through the recognition of a cellular protein that interacts with EBNA 2; the 130K protein identified by Gr/isser et al. (1993) would be a prime candidate for this role. However, the near-quantitative precipitation of EBNA 2 overexpressed in recombinant vaccinia virus-infected cells (Fig. 5a ) argues against this interpretation. We are therefore drawn to the conclusion that the E3cA10 antibody is indeed cross-reactive with EBNA 2, and that it recognizes a conformational epitope. This is consistent with the observation that in Western blots the antibody fails to recognize EBNA 2 but does recognize EBNA 3c. If E3cA 10 is indeed cross-reactive with a conformational epitope on EBNA 2, then the recognition of Type-1 but not Type-2 EBNA 2 proteins ( Fig. 2 and 4 ) may be significant in the context of the biological properties of the two types of EBNA 2 .
